Carbohydrate Antigen 125-guided Therapy in Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

May 31, 2015

Conditions
Heart Failure
Interventions
DRUG

CA125 guided strategy

Up titration of loop diuretics according to plasma levels of CA125 in the active arm

DRUG

CA125 guided strategy

Consider statins in all patients in the active arm

DRUG

CA125 guided strategy

Consider omega-3 polyunsaturated fatty acids in the active arm

OTHER

CA125 guided strategy

Frequency of monitoring according plasma evolution of CA125 in the active arm.

DRUG

Standard treatment strategy

All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).

DRUG

CA125 guided strategy

All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).

Trial Locations (1)

46010

Hospital Clínico Unbiversitario de Valencia, Valencia

All Listed Sponsors
collaborator

Ministerio de Sanidad, Servicios Sociales e Igualdad

OTHER_GOV

lead

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

NCT02008110 - Carbohydrate Antigen 125-guided Therapy in Heart Failure | Biotech Hunter | Biotech Hunter